177 related articles for article (PubMed ID: 22944293)
21. Prognostic value of phosphorylated mTOR/RPS6KB1 in non- small cell lung cancer.
Zhang Y; Ni HJ; Cheng DY
Asian Pac J Cancer Prev; 2013; 14(6):3725-8. PubMed ID: 23886172
[TBL] [Abstract][Full Text] [Related]
22. Downregulation of p70S6K Enhances Cell Sensitivity to Rapamycin in Esophageal Squamous Cell Carcinoma.
Lu Z; Peng K; Wang N; Liu HM; Hou G
J Immunol Res; 2016; 2016():7828916. PubMed ID: 27595116
[TBL] [Abstract][Full Text] [Related]
23. Downregulation of SIRT4 Expression Is Associated with Poor Prognosis in Esophageal Squamous Cell Carcinoma.
Nakahara Y; Yamasaki M; Sawada G; Miyazaki Y; Makino T; Takahashi T; Kurokawa Y; Nakajima K; Takiguchi S; Mimori K; Mori M; Doki Y
Oncology; 2016; 90(6):347-55. PubMed ID: 27082627
[TBL] [Abstract][Full Text] [Related]
24. Prognostic Significance of mTOR and PTEN in Patients with Esophageal Squamous Cell Carcinoma.
Lu J; Pan Y; Xia X; Gu Y; Lei Y
Biomed Res Int; 2015; 2015():417210. PubMed ID: 26357655
[TBL] [Abstract][Full Text] [Related]
25. A dual mTORC1 and mTORC2 inhibitor shows antitumor activity in esophageal squamous cell carcinoma cells and sensitizes them to cisplatin.
Huang Y; Xi Q; Chen Y; Wang J; Peng P; Xia S; Yu S
Anticancer Drugs; 2013 Oct; 24(9):889-98. PubMed ID: 23838676
[TBL] [Abstract][Full Text] [Related]
26. Cripto-1 acts as a functional marker of cancer stem-like cells and predicts prognosis of the patients in esophageal squamous cell carcinoma.
Liu Q; Cui X; Yu X; Bian BS; Qian F; Hu XG; Ji CD; Yang L; Ren Y; Cui W; Zhang X; Zhang P; Wang JM; Cui YH; Bian XW
Mol Cancer; 2017 Apr; 16(1):81. PubMed ID: 28431580
[TBL] [Abstract][Full Text] [Related]
27. Anti-tumor effect of the mammalian target of rapamycin inhibitor everolimus in oral squamous cell carcinoma.
Naruse T; Yanamoto S; Yamada S; Rokutanda S; Kawakita A; Kawasaki G; Umeda M
Pathol Oncol Res; 2015 Jul; 21(3):765-73. PubMed ID: 25682238
[TBL] [Abstract][Full Text] [Related]
28. Efficacy of system l amino acid transporter 1 inhibition as a therapeutic target in esophageal squamous cell carcinoma.
Ohshima Y; Kaira K; Yamaguchi A; Oriuchi N; Tominaga H; Nagamori S; Kanai Y; Yokobori T; Miyazaki T; Asao T; Tsushima Y; Kuwano H; Ishioka NS
Cancer Sci; 2016 Oct; 107(10):1499-1505. PubMed ID: 27465934
[TBL] [Abstract][Full Text] [Related]
29. The mTOR Pathway Regulates PKM2 to Affect Glycolysis in Esophageal Squamous Cell Carcinoma.
Xiaoyu H; Yiru Y; Shuisheng S; Keyan C; Zixing Y; Shanglin C; Yuan W; Dongming C; Wangliang Z; Xudong B; Jie M
Technol Cancer Res Treat; 2018 Jan; 17():1533033818780063. PubMed ID: 29916308
[TBL] [Abstract][Full Text] [Related]
30. RICTOR expression in esophageal squamous cell carcinoma and its clinical significance.
Jiang WJ; Feng RX; Liu JT; Fan LL; Wang H; Sun GP
Med Oncol; 2017 Mar; 34(3):32. PubMed ID: 28132115
[TBL] [Abstract][Full Text] [Related]
31. TRPV6 plays a new role in predicting survival of patients with esophageal squamous cell carcinoma.
Zhang SS; Xie X; Wen J; Luo KJ; Liu QW; Yang H; Hu Y; Fu JH
Diagn Pathol; 2016 Jan; 11():14. PubMed ID: 26818094
[TBL] [Abstract][Full Text] [Related]
32. TDO2 Overexpression Is Associated with Cancer Stem Cells and Poor Prognosis in Esophageal Squamous Cell Carcinoma.
Pham QT; Oue N; Sekino Y; Yamamoto Y; Shigematsu Y; Sakamoto N; Sentani K; Uraoka N; Yasui W
Oncology; 2018; 95(5):297-308. PubMed ID: 30134247
[TBL] [Abstract][Full Text] [Related]
33. MicroRNA-100 promotes migration and invasion through mammalian target of rapamycin in esophageal squamous cell carcinoma.
Zhang N; Fu H; Song L; Ding Y; Wang X; Zhao C; Zhao Y; Jiao F; Zhao Y
Oncol Rep; 2014 Oct; 32(4):1409-18. PubMed ID: 25109390
[TBL] [Abstract][Full Text] [Related]
34. Targeted inhibition of mTOR signaling improves sensitivity of esophageal squamous cell carcinoma cells to cisplatin.
Hou G; Yang S; Zhou Y; Wang C; Zhao W; Lu Z
J Immunol Res; 2014; 2014():845763. PubMed ID: 24818169
[TBL] [Abstract][Full Text] [Related]
35. Overexpression of TRIM44 is related to invasive potential and malignant outcomes in esophageal squamous cell carcinoma.
Kawaguchi T; Komatsu S; Ichikawa D; Hirajima S; Nishimura Y; Konishi H; Shiozaki A; Fujiwara H; Okamoto K; Tsuda H; Otsuji E
Tumour Biol; 2017 Jun; 39(6):1010428317700409. PubMed ID: 28618928
[TBL] [Abstract][Full Text] [Related]
36. Epigenetic silencing of HIC1 promotes epithelial-mesenchymal transition and drives progression in esophageal squamous cell carcinoma.
Li P; Liu X; Dong ZM; Ling ZQ
Oncotarget; 2015 Nov; 6(35):38151-65. PubMed ID: 26510908
[TBL] [Abstract][Full Text] [Related]
37. ZNF750 Expression Is a Potential Prognostic Biomarker in Esophageal Squamous Cell Carcinoma.
Otsuka R; Akutsu Y; Sakata H; Hanari N; Murakami K; Kano M; Toyozumi T; Takahashi M; Matsumoto Y; Sekino N; Yokoyama M; Okada K; Shiraishi T; Komatsu A; Iida K; Matsubara H
Oncology; 2018; 94(3):142-148. PubMed ID: 29216641
[TBL] [Abstract][Full Text] [Related]
38. Long Non-Coding RNA (lncRNA) Growth Arrest Specific 5 (GAS5) Suppresses Esophageal Squamous Cell Carcinoma Cell Proliferation and Migration by Inactivating Phosphatidylinositol 3-kinase (PI3K)/AKT/Mammalian Target of Rapamycin (mTOR) Signaling Pathway.
Wang G; Sun J; Zhao H; Li H
Med Sci Monit; 2018 Oct; 24():7689-7696. PubMed ID: 30368517
[TBL] [Abstract][Full Text] [Related]
39. The overexpression of DBC1 in esophageal squamous cell carcinoma correlates with poor prognosis.
Kim SH; Kim JH; Yu EJ; Lee KW; Park CK
Histol Histopathol; 2012 Jan; 27(1):49-58. PubMed ID: 22127596
[TBL] [Abstract][Full Text] [Related]
40. Overexpression of activator of G-protein signaling 3 decreases the proliferation of esophageal squamous cell carcinoma.
Shi H; Ren H; Yang X; Zhu H; Yao L; Hang Q; Mao H; Huang Y; Zhang J; Wang Y
Pathol Res Pract; 2015 Jun; 211(6):449-55. PubMed ID: 25812748
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
